login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

First patient enrolled in REPRISE II trial to evaluate the safety and performance of the Lotus Valve System


Thursday, 11 Oct 2012 11:23

On 10 October 2012, Boston Scientific announced it has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus Valve System in up to 120 patients with severe aortic valve disease.

This international, multicentre study includes 15 sites in Australia, France, Germany and the UK. According to Boston Scientific, the Lotus Valve System is the first transcatheter aortic valve implantation (TAVI) device of its kind that is designed to minimise aortic regurgitation. The device is both fully repositionable and retrievable prior to release, offering predictable and precise placement. The results of the REPRISE II trial are expected to be used to support CE mark and other international regulatory approvals.

“We were encouraged by the promising results of the REPRISE I clinical trial completed earlier this year and we are therefore very confident about evaluating the safety and performance of the Lotus Valve in a larger patient cohort,” said Ian Meredith, director of Monash Heart, at Monash Medical Centre in Melbourne, Australia, and the principal investigator of the REPRISE II trial. “The Lotus Valve has a number of important features which address some of the limitations observed with the first generation devices. The ease of use, predictable and precise positioning, and the ability to fully reposition and retrieve the Lotus Valve offer the operator considerable reassurance and control. These features, along with the minimised risk of paravalvular leakage, may lead to improved clinical outcomes.”

The Lotus Valve System is a differentiated second-generation TAVI technology, which consists of a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system used for guidance and percutaneous placement of the valve. The low-profile delivery system and introducer sheath are designed to enable predictable and precise placement, as well as bidirectional atraumatic repositioning and retrieval at any time prior to release of the aortic valve implant. The device also employs a unique Adaptive Seal feature designed to minimise the incidence of paravalvular regurgitation, which has proven to be a predictor of mortality.

Current study enrolment requires that patients have severe calcified aortic stenosis, are aged 70 years or older and are considered to be at high surgical risk, defined as an STS (Society of Thoracic Surgeons) mortality score >8 or the consensus opinion of the Heart Team. The REPRISE II study is designed to study two valve sizes, 23mm and 27mm, and have a five-year follow-up. Beyond that, it will assess for other endpoints recommended by the Valve Academic Research Consortium (VARC) and regulatory agencies. Study enrolment is expected to be completed in the first half of 2013.

“There is a high need for continued evolution of device technology to treat people with severe aortic valve disease,” said Keith D Dawkins, global chief medical officer for Boston Scientific. “We are looking forward to advancing the Boston Scientific valve program with REPRISE II, as we believe the Lotus Valve System is a unique technology that will offer interventional cardiologists greater precision and control in deployment which, in effect, may simplify the implantation procedure and lead to improved patient outcomes.”

The Lotus Valve System is an investigational device, limited by applicable law to investigational use and not available for sale. The device was developed by Sadra Medical, which Boston Scientific acquired in 2011.




Add New Comment

Related Items


Most popular


European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction
Wednesday, 08 Jun 2016
Karl-Heinz Kuck has withdrawn his candidacy for president-elect of the European Society of Cardiology (ESC) and also resigned from board of the European Heart Rhythm Association (EHRA). This follows ... Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction

Biotronik’s scaffold is now approved for use in Europe
Wednesday, 15 Jun 2016
Biotronik’s bioresorbable magnesium scaffold—Magmaris—is now CE mark approved, meaning it is now one of three bioresorbable scaffolds available on the European market (alongside Abbott Vascular’s A... Biotronik’s scaffold is now approved for use in Europe

Features


TAVI durability: A rose by any other name is still a rose
Wednesday, 20 Jul 2016
The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter ... TAVI durability: A rose by any other name is still a rose

Exploring the borders of TAVI
Monday, 11 Jul 2016
The NOTION 2 trial, which recently enrolled a 64-year-old female with Society of Thoracic Surgeon (STS) score 1.2% as its first patient, is comparing the use of TAVI with the use of surgical aortic ... Exploring the borders of TAVI

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions